Company* |
Funding |
Amount (M) |
Type# |
Details (Date) |
| | ||||
Aastrom Biosciences Inc. (ASTM) |
National Institute of Biomedical Imaging and Bioengineering |
$0.101 |
Phase I SBIR grant |
To support the development of system to produce a variety of primary human cell types (5/21) |
Aastrom Biosciences Inc. (ASTM) |
National Institutes of Health |
$0.1 |
Phase I SBIR grant |
For six-month study to develop a bone marrow stem cell-based treatment of circulatio ischemia caused by vascular diseases and diabetes (10/6) |
Aastrom Biosciences Inc. (ASTM) |
National Institute of Diabetes and Digestive and Kidney Diseases |
$0.443 |
Phase I SBIR grant |
To support studies to optimize the production of Aastrom's Tissue Repair Cells for the clinical generation of normal human tissue (6/18) |
Aastrom Biosciences Inc. (ASTM) |
National Institutes of Health |
$0.11 |
Phase I SBIR grant |
To support investigations to expand the company's development of stem cell-based approaches for regeneration of bone in patients requiring a bone graft treatment (7/2) |
Aastrom Biosciences Inc. (ASTM) |
National Institutes of Health |
ND |
SBIR grant |
To demonstrate the feasibility of using the AastromReplicell System for the production of completed dendritic cell-based vaccines for the immunotherapy of ovarian cancer (9/15) |
ActivX Biosciences Inc.* |
National Cancer Institute |
$1.1 |
Phase II SBIR |
To fund the establishment of toxicity profiles and the identification of key proteins involved in toxicities and adverse events associated with known toxic agents (6/30) |
Advanced Life Sciences Inc.* |
National Institutes of Health |
ND |
SBIR grant |
For a proteomics-based technology that eventually could lead to treatment of diseases that arise from the faulty aggregation of proteins, such as Alzheimer's (6/25) |
Advanced Targeting Systems Inc.* |
National Institute of Mental Health |
$2.4 |
Phase II SBIR grant |
To fund development of a drug for chronic pain, and allow company to prepare for human testing (10/7) |
Agennix Inc.* |
National Institute of Arthritis and Musculoskeletal and Skin Diseases |
$0.85 |
Phase I/II SBIR grant |
To support an initial clinical safety study and a randomized, placebo-controlled efficacy trial for recombinant human lactoferrin gel in patients with diabetic neuropathic foot ulcers (9/17) |
AlphaMed Inc.* |
National Cancer Institute |
$0.5 |
STTR grant |
To develop a targeted radiotherapy for metastatic melanoma (8/13) |
AlphaVax Inc.* |
National Institute of Allergy and Infectious Diseases |
$16.6 |
Biodefense grants |
A $9.1M grant to develop a vaccine against botulinum neurotoxins and a $7.5M grant for a vaccine against equine encephalomyelitis; the grants will be spread over four and a half years and fun work through a Phase I trial (9/29) |
Althea |
National Cancer Institute |
ND |
Phase I SBIR grant |
To develop a production-oriented, high-throughput approach to gene expression analysis for cancer (5/5) |
Altus Biologics Inc.* |
National Institute of Diabetes and Digestive and Kidney Diseases |
$0.75 |
Phase II SBIR grant |
Two years of funding for development of enzyme therapy ALTU-140 for chronic abdominal pain (10/7) |
Amsterdam Moleclar Therapeutics BV* (the Netherlands) |
Dutch Ministry of Economic Affairs |
|1.8 (US$2.1) |
Grant |
For the preclinical development of ex vivo gene therapy using interleukin-10 in patients suffering from Crohn's disease (9/2) |
Antigen Express Inc.* (acquired by Generex Biotechnology Corp.) |
National Institute of Allergy and Infectious Diseases |
$0.357 |
SBIR grant |
To support development of an HIV/DNA vaccine using Antigen Express's technology for boost- ing antigen-specific T-helper cell responses (5/23) |
Aphios Corp.* |
National Center for Complementary and Alternative Medicine |
ND |
Phase I SBIR grant |
To develop a smallpox thera- peutic from marine microorganisms; Aphios plans to discover therapeutics by screening its library of marine molecules against Vaccinia variola (9/9) |
Asteran Inc.* |
State of Michigan |
$2.3 |
Grant from tobacco settlement |
Asteran is part of joint program to apply genomics technology to its tissue bank to speed discovery of drugs and diagnostics for cancer (9/25) |
Avanir Pharmaceuticals |
National Institutes of Health |
$0.1 |
SBIR grant |
To fund initial development of human monoclonal antibodies for human cytomegalovirus infection using its Xenerex technology (5/6) |
Avanir Pharmaceuticals Inc. (AMEX:AVN) |
National Institute of Allergy and Infectious Diseases |
$0.1 |
SBIR grant |
For work on fully human antibody to anthrax toxins that was begun under a Department of Defense grant (10/13) |
BioCryst Pharmaceuticals Inc. (BCRX) |
National Institute of Allergy and Infectious Diseases |
$0.6 |
Phase I SBIR grant |
To support BioCryst's efforts to develop its preclinical product candidates for the treatment of hepatitis C (7/8) |
Biolog Inc.* |
National Cancer Institute |
$0.25 |
SBIR grant |
For a project applying Biolog's Phenotype MicroArray assay platform in toxicological cell-based assays (6/9) |
Biolog Inc.* |
National Institute of Allergy and Infectious Diseases |
$2.28 |
Grant |
To fund additional development of detection and identification methods for the most important bacteria, including those that could be used in acts of bioterrorism (9/8) |
BioSante Pharmaceutials Inc. (OTC BB:BISP) |
National Institutes of Health |
$0.1 |
SBIR grant |
To fund product development work on BioSante's calcium phosphate particulate delivery technology for oral insulin (9/8) |
BioSeek Inc.* |
National Institutes of Health |
ND |
Phase II SBIR grant |
To support the expansion of BioSeek's BioMAP technology for compound validation and prioritization in human primary cell-based inflammatory disease models (6/10) |
Biosyn Inc.* |
International Partnership for Micobicides |
$10 |
Private grant |
Biosyn would make the product available to developing nations as part of the deal with IPM, which is paying up to $10M in milestone-driven funding (10/2) |
Biota Holdings Ltd. (Australia; ASX:BTA) |
Australian government |
A$2.7 (US$1.77) |
R&D Start Grant |
To advance Biota's respiratory syncytial virus drug development program (5/19) |
BioPort Corp.* |
National Institutes of Health |
$0.646 |
Grant |
To investigate development of technology for DNA delivery of vaccines; the work will be done with Therapeutic Systems Research Laboratories Inc. and the University of Michigan (10/14) |
Callisto Pharmaceutical Inc. (OTC BB:CLSP) |
National Institutes |
$0.265 |
STTR grant |
To study mechanism of action and properties of Atiprimod, a candidate for multiple myeloma (10/7) |
Cel-Sci Corp. (AMEX:CVM) |
National Heart, Lung and Blood Institute |
$0.134 |
SBIR grant |
To further develop a treatment for autoimmune myocarditis (4/23) |
Cel-Sci Corp. (AMEX:CVM) |
National Institute of Allergy and Infectious Diseases |
$0.162 |
Phase I SBIR grant |
To develop CEL-1000 against herpes (5/7) |
Cel-Sci Corp. (AMEX:CVM) |
National Institute of Allergy and Infectious Diseases |
$0.104 |
Phase I SBIR grant |
To develop CEL-1000 for vaccinia and smallpox infections as a single agent and as an adjuvant for vaccines (9/29) |
ChemoCentryx |
National Institute of Allergy and Infectious Diseases |
$14 |
Research grant |
To develop immune-modulatory agents for infectious disease that may be caused by biological warfare pathogens (10/13) |
Chesapeake |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To genetically transform caterpillars so they produce humanized glycoprotein modifications (9/12) |
Chimerix Inc.* |
National Institute of Allergy and Infectious Diseases |
$36.1 |
Grant |
To continue development of an oral antiviral drug for smallpox infections and complications resulting from vaccinations (9/10) |
Chromatin Inc.* |
National Institute of Standards and Technology, and Nationa Institutes of Health |
$2.7 |
Grants |
Grants from the NIST's Advanced Technology Program and the NIH will go toward development of minichromosomes for introduction of genes into plants (9/24) |
Chrysalis BioTechnology |
National Institutes of Health |
$0.095 |
SBIR grant |
To fund the study of a topical peptide drug candidate intended to enhance the body's ability to fight microbial infections (6/24) |
Cognia Corp.* |
National Science Foundation |
ND |
SBIR grant |
To further develop a protein-trafficking database module and augment its information management system, Cognia Molecular (4/24) |
CompleGen Inc.* |
National Institutes of Health |
$0.3 |
SBIR grant |
To apply its XenoGene system to the discovery of antitrypanosomal drugs (5/6) |
Cubist Pharmaceuticals |
National Institutes |
$0.5 |
Phase I SBIR grants |
Two grants for research on lipopeptides, which may prove to be a source of anti-infective medicines (7/29) |
Cumbre Inc.* |
National Institute of Allergy and Infectious Diseases |
ND |
SBIR grant |
To support studies to investigate the potential of a synthetic chemistry series for development as a new tuberculosis drug (5/20) |
Cyntellect Inc. (subsidiary of Oncosis LLC*) |
National Center for Research Resources |
ND |
SBIR grant |
To continue the development of Cyntellect's Laser-Enabled Analysis and Processing (LEAP) platform for applications in drug discovery and cell-based screening (8/12) |
Cyntellect Inc. (subsidiary of Oncosis LLC*) |
National Human Genome Research Institute |
$0.183 |
Phase I SBIR grant |
To study high-throughput gene silencing by using Cyntellect's LEAP platform for opto-injection of nucleic acids, causing subsequent RNA interference (7/17) |
|
CyThera Inc.*
|
National Institute of Diabetes and Digestive and Kidney Diseases |
$0.665 |
Research and |
To establish in vivo proof of concept for its cell differentiation technology (6/4) |
Diversa Corp. (DVSA) |
National Institute of Allergy and Infectious Diseases |
$3.2 |
Grant |
To optimize three key antibodies for the detection of ricin toxin, plague and alpha-virus (7/25) |
Diversa Corp. (DVSA) |
National Institute of Allergy and Infectious Diseases |
ND |
Biodefense grant |
For Diversa to employ its ad- vanced proteomics capabilities to identify potential new targets associated with anthrax and plague virulence, and use validated targets to screen for therapeutic antibodies from Diversa's de novo human antibody platform (8/12) |
DNAPrint |
National Institutes of Justice |
$0.05 |
Research grant |
To assist the institute as a subcontractor to map genetic markers of a certain forensics value considered by the company to be complementary to its DNAWitness efforts; DNA will be paid about $50,000 to produce about 80,000 genotypes (8/25) |
DOR BioPharma Inc. (AMEX:DOR) and University of Texas Southwestern Medical Center |
National Institute of Allergy and Infectious Diseases |
$2.6 |
Grant |
To further preclinical studies on the safety and efficacy of a recombinant ricin vaccine using a ricin aerosol challenge, and to compare formulations of the vaccine (9/15) |
DOR BioPharma Inc. (AMEX:DOR) |
National Institute of Allergy and Infectious Diseases |
$0.15 |
Phase I SBIR grant |
To support further development of MicroVax technology for oral and intranasal delivery of ricin vaccine (9/15) |
Dynavax Technologies |
National Institute of Allergy and Infectious Diseases |
$8.4 |
Biodefense grants |
The three grants will be applied to development of infectious disease products based on immunostimulatory DNA sequences; included are an anthrax vaccine, an influenza vaccine and an aerosolized product for enhancing lung response to airborne pathogens (9/29) |
DynPort Vaccine Co. LLC (UK; joint venture between Computer Sciences Corp. and Porton International Inc.) |
National Institute of Allergy and Infectious Diseases |
$11 |
Grant |
To develop the manufacturing processes for safe and efficacious vaccines that will protect against all known forms of botulinum neurotoxins within five years (9/4) |
Echelon Biosciences Inc.* |
National Institutes of Health |
$0.6 |
Research grant |
To accelerate Echelon's ability to evaluate specific cell-signaling pathway that are key initiator to a number of abnormal cell states (5/30) |
Echelon Biosciences Inc.* |
National Institutes of Health |
$0.1 |
Research grant |
To advance Echelon's drug discovery work related to tuberculosis (6/30) |
Eksigent Technologies* |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To fund development of Eski- gent's ChipLC system, which is designed to allow rapid, highly parallel chip-based chemical analysis based on high-performance liquid chromatography (9/11) |
Elusys Therapeutics Inc.* |
U.S. Department of Defense |
$3.5 |
Grant |
To further develop its heteropolymer drug to remove anthrax toxin from the bloodstream (9/22) |
Encelle Inc.* |
National Institutes of Health |
$1.7 |
SBIR grant |
For development of E-Matrix for diabetic foot wounds (5/23) |
Enodar Biologic* |
National Institutes of Health |
ND |
Grant |
To validate statistical methods and develop software tools for single nucleotide polymorphisms (6/16) |
Epimmune Inc. (EPMN) |
National Cancer Institute |
$0.6 |
Grant |
To support continued epitope analogue identification and preclinical development of multi-epitope, analogue-based cancer vaccines (7/28) |
EraGen |
National Institute of Allergy and Infectious Diseases |
ND |
Biodefense grant |
To develop multiple diagnostic products using its GeneCode System (9/9) |
EvoGenix Pty Ltd.* (Australia) |
Australia government |
A$0.9 (US$0.592) |
START grant |
To support EvoGenix's therapeutics development program over the next two years; EvoGenix will apply its technology for altering and optimizing proteins to the development of a protein pharmaceutical for the treatment of osteoporosis (5/27) |
Evolutionary Genomics* |
National Science Foundation |
ND |
Phase I SBIR grant |
To support a project with the goal of enabling AIDS drug development based on the genetic factors underlying the successful adaptations by humans' closest primate relatives, chimpanzees, to HIV-type viruses (6/6) |
FeRx Inc.* |
National Cancer Institute |
$0.64 |
Phase II SBIR grant |
To support research to continue the development of intratumoral radiation therapy of liver lesions using FeRx's MagneTarg drug delivery system (7/21) |
FibroGen Inc.* |
National Cancer Institute |
ND |
Phase I SBIR grant |
To support the development of new cancer agents targeting connective tissue growth factor, which promotes angiogenesis (7/9) |
Gamida-Cell Ltd. (Israel) |
Israeli government |
$1.4 |
Grants |
For StemEx, which is designed to expand the stem cell supply without differentiation and is applicable to both umbilical cord blood stem cells and stem cells from adult organs (6/16) |
GeneGo Inc.* |
Michigan Life Science Corridor |
$1.4 |
Grant |
To further develop its MetaCore platform and expand sales, customer support and application divisions (6/16) |
Generex Biotechnology Corp. (Canada; GNBT) |
National Cancer Institute |
ND |
SBIR grant |
To develop a T-helper-cell breast cancer vaccine (8/14) |
Generex Biotechnology Corp. (Canada; GNBT) |
National Cancer Institute |
$0.444 |
SBIR grant |
To support development of a vaccine for T-helper-cell breast cancer vaccines to treat malignant melanoma (9/15) |
GeneSoft Pharmaceuticals |
Defense Advanced Research Project Agency |
$5.5 |
Grant |
To develop countermeasures for biological warfare agents such as anthrax, smallpox and malaria (4/18) |
Genomatica Inc. |
Department of Energy |
$0.75 |
Phase II SBIR grant |
To continue developing its modeling technology for bioprocessing- and fermentation-related applications (8/6) |
Genomic Profiling Systems Inc.* |
National Institutes of Health |
$0.12 |
Phase I SBIR grant |
To develop Genomic Profiling's MultiPath test for detection of a spectrum of biological warfare agents (5/19) |
GenVec |
Maryland Technology Enterprise and Institute of the University of Maryland |
$0.1 |
Maryland Industrial Partnerships award |
To help fund research in the regeneration of hair cells in the inner ear, which could have the potential for treating hearing loss and balance disorders (8/19) |
GlycoFi Inc.* |
National Institutes of Health |
$1 |
Phase II SBIR grant |
To support a research project to develop GlycoFi's approach for the engineering of humanized yeast strains (9/24) |
Gryphon Therapeutics Inc.* |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To fund the company's program to validate a drug development platform designed to generate peptides composed of D-amino acids as pharmaceuticals (9/15) |
Guilford Pharmaceuticals Inc. (GLFD) |
National Institutes of Health |
$5.5 |
Grant |
To support work at Johns Hopkins to study Guilford's neuroimmunoligin technology in the area of sensory neuropathy (9/23) |
Guilford Pharmaceuticals Inc. (GLFD) |
National Cancer Institute |
$0.14 |
Phase I SBIR grant |
To evaluate feasibility of using a novel NAALADase inhibitor to provide targeted prostate cancer chemotherapy (9/23) |
Guilford Pharmaceuticals Inc. (GLFD) |
Ataxia Telangiectasia Children's Project |
$0.075 |
Grant |
To study Gulford's PARP-inhibitors as chemosensitizers (9/23) |
HandyLab Inc.* |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To develop a highly sensitive, low-cost, portable, broad-spectrum DNA analysis device using electrochemical detection (7/15) |
Icogen Corp.* |
National Institute of Aging [of the National Institutes of Health] |
ND |
SBIR grant |
To develop an Alzheimer's disease therapeutic (7/28) |
Incara Pharmaceuticals Corp. (OTC BB:INCR) |
National Cancer Institute |
$0.1 |
Phase I SBIR grant |
To study antitumor and radiation- protective effects of Incara's catalytic antioxidants (8/20) |
Inhibitex Inc.* |
FDA Office of Orphan Products Development |
$0.3 |
Orphan drug grant |
To help fund development of Veronate, an antibody-based drug being developed to prevent hospital-acquired [S. aureus]- infections in low-birth-weight infants (10/7) |
Insert Therapeutics Inc.* |
National Cancer Institute |
ND |
Phase I Flexible System to Advance Innovative Research grant |
To support the development of Insert's nonviral nucleic acid delivery system, called Cyclosert, for targeted systemic delivery of the interferon-alpha gene to tumors (7/24) |
Isis Pharmaceuticals Inc. (ISIS) |
Centers for Disease Control and Prevention |
$6 |
Grant |
To develop and apply diagnostic technology to surveillance of human and animal infectious diseases in the U.S. (10/7) |
Ixion Biotechnology Inc.* |
National Institutes of Health |
$0.76 |
Phase II SBIR grant |
To allow continued development of a coating technology to be applied to urinary tract stents; Ixion plans to use the coating technology to develop a prototype enzyme-coated stent to be tested for its ability to prevent encrustation and bacterial adhesion in an animal model that closely mimics the human urinary tract (7/10) |
Kucera Pharmaceutical |
National Institute of Allergy and Infectious Diseases and the National Institutes of Health |
ND |
SBIR grant |
To continue research and development of an anti-HIV compound, KPC-2 (6/5) |
Kucera Pharmaceutical |
North Carolina Biotechnology Center |
ND |
SBIR grant |
To complete preclinical development of KPC-2, an anti-HIV agent (9/22) |
Large Scale Biology Corp. (LSBC) |
National Institute of Allergy and Infectious Diseases |
ND |
Research grant |
Two-year grant to investigate potential of LSBC's plant viral vector technology for producing HIV vaccines (9/24) |
MaxCyte Inc.* |
National Institutes of Health |
$0.096 |
Phase I SBIR grant |
To develop MaxCyte's streamlining electroporation system, a high-speed cell-loading instrument for large volumes of cells (8/12) |
Mendel Biotechnology Inc.* |
U.S. Department of Agriculture |
ND |
Phase II SBIR grant |
To fund research to discover and develop plant genes that control the production of latex rubber (10/7) |
MicroIslet Inc. (OTC BB:MIIS) |
Juvenile Diabetes Research Foundation |
$0.25 |
Research grant |
To support ongoing preclinical studies of cell transplantation technologies for the treatment of insulin-dependent diabetes (6/30) |
MicroIslet Inc. |
National Institutes of Health |
$0.12 |
Phase I SBIR grant |
To develop its islet cell transplantation technology for treatment of insulin-dependent diabetes (5/28) |
Molecular Probes Inc.* |
National Cancer Institute |
ND |
SBIR grant |
To fund a research project to examine the reduced risk of breast cancer observed following a full-term pregnancy in early adulthood (4/27) |
Molecular Insight Pharmaceuticals Inc.* and McLean Hospital |
National Institutes of Health |
ND |
Grants |
One grant to fund development of radiopharmaceuticals to identify changes in the dopamine transporter, with potenital for diagnosis and monitoring of therapies, and a second to build on earlier research of the role of the dopamine D4 receptor in ADHD (10/16) |
Molecular Insight Pharmaceuticals Inc.* and Syracuse University |
National Institute of Allergy and Infectious Diseases |
ND |
Grant |
To develop peptide libraries that incorporate chelate chemistry as imaging probes for visualizing infection (10/16) |
MultiCell Technologies Inc. (subsidiary of Exten Industries Inc.; OTC BB:EXTI) |
National Institutes of Health |
ND |
Phase I SBIR grant |
To study metabolic pathways for MultiCell's immortalized human liver cells (8/13) |
Nature Technology Corp. |
National Institutes of Health |
$0.142 |
SBIR grant |
To develop gene-targeting technology aimed at tissue-specific expression of genes during gene therapy (8/8) |
NewNeural Inc.* |
National Institutes of Health |
$1.4 |
Five-year grant |
For work by NewNeural's founder and chief scientific officer on neural replacement strategies using cells produced from adult human bone marrow (7/22) |
Northwest Biotherapeutics Inc. (OTC BB:NWBT) |
National Institutes of Health |
$0.645 |
Two-year grant |
To research immunotherapy products that generate and enhance immune system responses to treat cancer (4/17) |
Novasite Pharmaceuticals Inc. (subsidiary of Applied Molecular Evolution Inc.; AMEV) |
National Institutes of Health |
$0.583 |
Phase I SBIR grants |
Three grants for crystallization of families of G protein-coupled receptors: serotonin, cannabinoid and EDG (9/17) |
Novasite Pharmaceuticals Inc. (subsidiary of Applied Molecular Evolution Inc.; AMEV) |
National Institutes of Health |
$0.5 |
Phase I SBIR grants |
Two grants for discovery of drug leads against G protein-coupled receptor subfamily of serotonin Type 2 receptors (10/14) |
Nucleonics Inc.* |
National Institute of Allergy and Infectious Diseases |
$1.6 |
Research grant |
To support research to develop reagents and methods for silencing hepatitis B virus gene expression and replication in vivo (9/25) |
NuGen Technologies Inc.* |
National Institutes of Health |
ND |
Phase I SBIR grant |
To support further development of its SPIA and Ribo-SPIA technologies for gene expression applications (10/7) |
Omrix Biopharmaceuticals Ltd.* (Israel) |
National Institutes of Health |
$3 |
Research grant |
To develop anti-bioterror injection intended to be used on healthy people surviving a first attack and as a prophylactic against the smallpox virus (8/6***) |
Oncosis LLC* |
National Science Foundation |
$0.1 |
Phase I SBIR grant |
To initiate an approach using the LEAP platform, created by Oncosis subsidiary Cyntellect Inc., to perform high throughput functional proteomics studies using chromophore assisted laser activities on live cells (6/24) |
One Cell |
National Science Foundation |
$0.51 |
Phase II SBIR grant |
To develop an approach for identifying hybridomas producing antigen-specific antibodies (7/14) |
Perlegen Sciences |
National Institutes of Health |
ND |
Grant |
For Perlegen to use its high- throughput oligonucleotide microarray technology to sequence the genomes of strains of salmonella to discover genetic variation among the strains (9/16) |
Pharmos |
Office of the Chief Scientist of Israel's Ministry of Industry and Trade (Israel) |
US$4.4 |
Grant |
For Pharmos' traumatic brain injury application for dexanabinol and to develop the bicyclic cannabinoid CB2-selective receptor agonist for prevention of cognitive impairment and to treat autoimmune and neurological diseases (5/28***) |
Phase |
National Institutes of Health |
ND |
Phase I SBIR grant |
To expand its deltaPhase technology into the biocatalysis and industrial enzyme markets (8/26) |
Phylonix Pharmaceuticals |
National Cancer Institute |
$0.951 |
Phase II SBIR grant |
To develop a zebrafish in vivo bioassay for screening anti-angiogenic drug candidates (6/30) |
PolyGenyx Inc.* |
National Human Genome Research Institute |
$0.998 |
SBIR grant |
To further develop PolyGenyx's SNP haplotyping platform, HaploScan, and to develop commercial haplotyping assays (6/25) |
Prima Biomed Ltd. (Australia; ASX:PRR) |
Australian Research Council |
A$0.3 (US$0.2) |
Grant |
For Prima Biomed subsidiary Panvax Ltd. to develop a vaccine for foot and mouth disease (6/19) |
Progenics Pharmaceuticals Inc. (PGNX) |
National Institutes of Health |
$7.7 |
Phase I SBIR grants |
For cancer immunotherapies, hepatitis C viral entry inhibition and for development and production of entry inhibitors to the human immunodeficiency virus (7/30) |
PTC Therapeutics Inc.* |
Department of Defense Neurofibromatosis Research Program |
ND |
Grant |
To enable PTC to apply its Small Molecule Modulation of Read-Through program to investigate compounds that promote read-through of nonsense mutations as a treatment for neurofibromatosis (4/25) |
PTC Therapeutics |
National Institute of Allergy and Infectious Diseases |
ND |
Phase II STTR grant |
To enable PTC to develop a virus- cell-based assay using HIV-1 vector systems for the discovery of drugs with anti-HIV activity (5/30) |
Ribonomics Inc.* |
U.S. Department of Defense |
$0.42 |
Grant |
To research post-transcriptional variations in breast cancer tissue to rapidly identify and develop new targets and biomarkers for therapy (8/14) |
SciClone Pharmaceuticals Inc. (SCLN) |
U.S. Department of Energy |
$0.84 |
Initiatives for Proliferation Prevention grant |
To develop an oral formulation of SCV-07, an immune enhancer for tuberculosis; the program is focused in the former Soviet Union (10/7) |
Sireen |
Bavarian Ministry of Economics (Germany) |
£400 (US$0.465) |
Research grant |
To fund program aimed at developing small-molecule inhibitors that target unregulated cell growth in cancer (10/15***) |
SRI International* |
National Cancer Institute |
ND |
Exploratory/ |
To develop in vitro assays using hepatobiliary cell systems (7/14) |
StemCells |
National Institute of Neurological Disease and Stroke |
$0.342 |
SBIR grant |
To further StemCells' work in the treatment of spinal cord injuries (9/8) |
SurroMed Inc.* |
National Institutes of Health |
ND |
SBIR grant |
For "Genetic Architecture of Autoimmune Diseases" related to SurroMed's analysis of serum for the identification of biological markers of autoimmune disease and genetic mapping of inheritable traits (8/6) |
Sygen International plc (UK; LSE: SNI) Foundation (U.S./Israel) |
Bionational Industrial Research and Development |
$1 |
Grant |
To conduct research into disease resistance and mortality in poultry (8/28) |
Targacept Inc.* |
National Institute of Standards and Technology |
$2 |
Advanced Technology Program grant |
To fund Targacept's development of new computer-simulation software designed to accurately predict biological and toxicological effects of drugs (9/11) |
Targacept Inc.* |
National Science Foundation |
ND |
Phase I SBIR grant |
To support Targacept's research to develop computer software designed to predict biological activity of small molecules (7/1) |
Teranode Corp.* |
National Institutes of Health |
$1.8 |
Grant |
To develop language and tools for communication and collaboration required by large-scale biology (6/25) |
Thios Pharmaceuticals Inc.* |
National Institutes of Health |
ND |
SBIR grant |
To develop antibodies for chronic inflammatory diseases such as asthma and rheumatoid arthritis (5/1) |
Tranzyme Inc.* |
North Carolina Biotechnology Center |
$0.15 |
Small business research award |
To accelerate applications of its TranzVector gene delivery technology in the area of gene silencing (9/23) |
Tranzyme Inc.* |
National Institute of Allergy and Infectious Diseases and National Institute on Aging |
$0.3 |
Phase I SBIR grant and Phase I STTR grant |
The NAIAD STTR grant is to validate a multireporter cell-based assay sensitive to HIV; the NIA SBIR grant is for development of neuronal cell-based assays and methods for validation of genes that modulate apoptosis (9/29) |
Tularik |
National Cancer Institute |
$0.5 |
Phase I SBIR grants |
To support development of new anticancer agents targeting KCNK9/TASK3 and WIP1/PP1MD (8/12) |
Unigene Laboratories Inc. (OTC BB:UGNE) |
National Institutes of Health |
$0.125 |
SBIR grant |
To use technology to identify peptides that may have therapeutic value (6/23) |
U.S. Genomics* |
National Science Foundation |
$0.5 |
Phase II SBIR grant |
To advance development of technology for rapid DNA analysis and genomic mapping (9/29) |
VaxGen |
National Institute of Allergy and Infectious Diseases |
$2 |
Phase II SBIR grant |
To identify antigens for potential use in future HIV vaccine candidates (6/10) |
Velcura Therapeutics Inc.* |
National Institute on Aging |
$0.224 |
Phase I SBIR grant |
To extend and refine studies into molecular processes underlying human bone formation (10/6) |
Vical Inc. (VICL) |
National Institute of Allergy and Infectious Diseases |
$5.7 |
Phase II SBIR grant |
To help fund the development of Vical's nonviral DNA vaccine against anthrax (6/30) |
Vion |
National Institute of Allergy and Infectious Diseases |
ND |
SBIR grant |
To support preclinical studies of Triapine in combination with nucleoside analogues against various viruses (10/1) |
Virogenomics |
National Institute of Allergy and Infectious Diseases |
$0.1 |
STTR grant |
To study human genes as drug targets for fighting HIV infection (5/29) |
ViroLogic |
National Institute of Allergy and Infectious Diseases |
$3 |
SBIR grants |
To support the development of analytical and database tools to facilitate the identification and characterization of drug-resistant strains of HIV and assays that will aid in the preclinical and clinical evaluation of the next generation of antiviral therapeutics (7/31) |
ViroLogic |
National Institute of Allergy and Infectious Diseases |
ND |
Grant |
To develop a hepatitis C virus drug-susceptibility assay; the project will focus on the development of rapid and sensitive assays to evaluate the susceptibility of HCV to investigational drugs that inhibit viral polymerase and protease (9/3) |
ViroPharma Inc. (VPHM) |
National Institute of Allergy and Infectious Diseases |
$2.26 |
Phase I SBIR grants |
To support development of small molecules for smallpox and hemorrhagic fever viruses (10/1) |
Xechem International Inc.* |
National Heart, Lung and Blood Institute |
ND |
Phase I SBIR grant |
To support development of Niprisan for treating patients with sickle-cell disease (10/16) |
Zen-Bio Inc.* |
National Institute of Diabetes and Digestive and Kidney Disease |
ND |
Phase I SBIR grant |
To develop visceral preadipocytes and adipocytes (9/12) |
TOTAL: $208.407M | ||||
| | ||||
Notes: | ||||
* Indicates a privately held company or institution. | ||||
** Unless otherwise indicated, symbols listed are on the Nasdaq market. | ||||
*** Denotes the date the item ran in BioWorld International. | ||||
# SBIR = Small Business Innovation Research; STTR =Small Business Technology Transfer. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board | ||||
